Acromegaly, Bone Diseases, Cardiovascular Diseases, Growth Hormone Treatment, Sleep Apnea
Conditions
Brief summary
The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment.
Detailed description
Acromegaly is a rare disease caused by a growth hormone (GH) producing pituitary adenoma. Surgery is primary treatment, whereas medical treatment with a somatostatin analogue (SA), which suppresses GH secretion and reduces tumour size, is used when surgery is insufficient or unfeasible. Acromegaly is associated with metabolic abnormalities which contributes to an increased morbidity and mortality if left untreated. To which extend these abnormalities reverses after treatment, and if treatment modality influences the outcome, remain elusive. The aim of the study is to investigate sleep apnea, circulation and metabolism in acromegaly before and after surgery and/or medical treatment
Interventions
None listed
Sponsors
University of Aarhus
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Recently diagnosed with acromegaly * Age above 18 * Written consent
Exclusion criteria
\- Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sleep apnea | At baseline (time of diagnosis) and at an average of 1 years treatment | ApneaLinkAir: respiratory effort, puls, oxygen saturation, nasal flow and snoring |
| Circulation | At baseline (time of diagnosis) and at an average of 1 years treatment | Sphygmocor: central arterial pressure and pulse wave velocity |
| Bone metabolism | At baseline (time of diagnosis) and at an average of 1 years treatment | HRpQCT scan |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body composition | At baseline (time of diagnosis) and at an average of 1 years treatment | DXA scan |
| Physical activity | At baseline (time of diagnosis) and at an average of 1 years treatment | Sensoriband |
| Heartfunction | At baseline (time of diagnosis) and at an average of 1 years treatment | Echocardiography |
| Substrate metabolism; signaling proteins | At baseline (time of diagnosis) and at an average of 1 years treatment | Western blotting |
| Substrate metabolism; gene targets | At baseline (time of diagnosis) and at an average of 1 years treatment | qPCR |
| Energy expenditure | At baseline (time of diagnosis) and at an average of 1 years treatment | Indirect calorimetry |
Countries
Denmark
Contacts
Primary ContactMai C Arlien-Søborg, MD
Backup ContactJens Otto L Jørgensen, Professor
Outcome results
None listed